Irbesartan/Hydrochlorothiazid - 1 A Pharma

Irbesartan, the active ingredient in Irbesartan/Hydrochlorothiazide - 1 A Pharma, is an Angiotensin II receptor blocker presented as an oral tablet for systemic use. It is combined with hydrochlorothiazide, a thiazide diuretic, to treat hypertension in adult patients.

GNH USA supplies Irbesartan/Hydrochlorothiazide - 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Irbesartan/Hydrochlorothiazide is indicated for hypertension, acting on the renin‑angiotensin system and promoting diuresis. - Hypertension: reduces systolic and diastolic blood pressure, helping prevent stroke and heart attack. - Isolated systolic hypertension: provides effective control in elderly patients. - Hypertensive renal protection: assists in slowing progression of kidney disease in patients with elevated blood pressure.

The combination may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: light‑headedness, especially after initial dosing. - Headache: mild to moderate intensity. - Increased urination: due to the diuretic component. - Electrolyte imbalance: mild reductions in potassium or sodium levels.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that can cause fainting. - Hyperkalemia: elevated potassium levels that may be dangerous. - Acute kidney injury: sudden decline in renal function. - Allergic reactions: rash, angioedema, or anaphylaxis.

Before prescribing Irbesartan/Hydrochlorothiazide, clinicians should consider several safety aspects. - Renal impairment: monitor kidney function and adjust therapy as needed. - Electrolyte disturbances: check serum potassium and sodium regularly. - Volume depletion: avoid in patients prone to dehydration or on high‑dose diuretics. - Pregnancy: contraindicated in the second and third trimesters; risk to fetus. - Concomitant drugs: review for interactions with potassium‑sparing agents or NSAIDs. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Irbesartan/Hydrochlorothiazide can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - ACE inhibitors or aliskiren: risk of additive renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: increased lithium levels, risk of toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effect and impair renal function. - Cyclosporine or tacrolimus: can increase serum creatinine. - Antidiabetic agents: diuretic may affect glucose control. - Beta‑blockers: may enhance hypotensive effect.